Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease
Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease have?
Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease has 78 citations in the OpenAlex counts ScholarIQ stores.
When was Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease published?
Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease has 2011 year in the ScholarIQ index.
What is the open-access status of Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease?
Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease has green oa status in the ScholarIQ index.
What is the DOI of Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease?
The DOI for Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease is on the source record.
What is the PMID of Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease?
The PMID for Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease is on the source record.
What is the OpenAlex record for Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease?
The OpenAlex for Long‐term safety and efficacy of deferasirox (Exjade<sup>®</sup>) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease is on the source record.